ea0089c7 | Clinical – Chemo/SSA/Biologics | NANETS2022
MPH Taymeyah Al-Toubah
, MD Eleonora Pelle
, MD Jonathan Strosberg
Background: The treatment landscape for neuroendocrine tumors includes alkylating-agent chemotherapy and peptide receptor radiotherapy (PRRT) with 177Lu-Dotatate. The risk of MDS/AML associated with 177Lu-Dotatate is approximately 2-3%. Several small prior studies have suggested substantially higher rates of MDS/AML (approximately 10%) in patients who have also received alkylating agent chemotherapy with streptozocin or temozolomide, either combined with PRRT or sequentially. ...